Drugs · acquisition-cost intelligence
LAMICTAL
lamotrigine· ingredient lamotrigine· LAMOTRIGINE 100 mg/1; LAMOTRIGINE 150 mg/1; LAMOTRIGINE 200 mg/1; LAMOTRIGINE 25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.60
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other lamotrigine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| LAMOTRIGINE Kit | $0.04556 | −$1.55 |
| Lamotrigine | $0.07759 | −$1.52 |
| lamotrigine | $0.16332 | −$1.43 |
| LAMICTAL XR | $0.77451 | −$0.82210 |
Medicare Part D coverage · CY2026
On 147 plan formularies · typical tier 4
Prior auth 0% · Step therapy 10% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.